10 June 2021 - Late treatment study
A pilot study on intravenous N-Acetylcysteine treatment in patients with mild-to-moderate COVID19-associated acute respiratory distress syndrome
et al., Pharmacological Reports, doi:10.1007/s43440-021-00296-2 (Peer Reviewed)
RCT 92 hospitalized patients, 47 treated with NAC, showing non-significant improvements in outcomes. IRCT20120215009014N355. NAC 40mg/kg/day intravenous for 3 days.
|
risk of death, 17.9% lower, RR 0.82, p = 0.65, treatment 12 of 47 (25.5%), control 14 of 45 (31.1%), NNT 18.
|
|
risk of mechanical ventilation, 13.8% lower, RR 0.86, p = 0.67, treatment 18 of 47 (38.3%), control 20 of 45 (44.4%), NNT 16.
|
|
ICU time, 20.0% lower, relative time 0.80, p = 0.48, treatment 47, control 45.
|
|
hospitalization time, 33.3% lower, relative time 0.67, p = 0.31, treatment 47, control 45.
|
|
risk of no recovery, 14.5% lower, RR 0.85, p = 0.41, treatment 25 of 47 (53.2%), control 28 of 45 (62.2%), NNT 11.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. |
Taher et al., 6/10/2021, Double Blind Randomized Controlled Trial, Iran, Middle East, peer-reviewed, 6 authors, average treatment delay 7.0 days.
Please send us
corrections, updates, or comments. Vaccines and treatments are both
valuable and complementary. All practical, effective, and safe means
should be used. Elimination of COVID-19 is a race against viral evolution. No
treatment, vaccine, or intervention is 100% available and effective for all
current and future variants. Denying the efficacy of any method increases
mortality, morbidity, collateral damage, and the risk of endemic status. We do
not provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. WCH
and FLCCC provide
treatment protocols.